Citalopram plus reboxetine in treatment-resistant obsessive-compulsive disorder.
While serotonin reuptake inhibitors (SRIs) are the first-line treatment of obsessive compulsive disorder (OCD), as many as 40-60% of patients fail to respond to adequate trials with these drugs. In this study, we describe the case of a patient with an SRI-resistant OCD who was successfully treated with a combination of citalopram (a selective SRI) and reboxetine (a selective noradrenaline reuptake inhibitor (SNRI)). This report suggests that future studies accessing the efficacy of the SRI SNRI combination in treatment resistant OCD are needed.
Fontenelle
Leonardo F
LF
Anxiety and Depression Research Program, Institute of Psychiatry of the Federal University of Rio de Janeiro, Rio de Janeiro, Brazil. leofontenelle@hotmail.com
Mendlowicz
Mauro V
MV
Miguel
Euripedes C
EC
Versiani
Marcio
M
D018759:Adrenergic Uptake Inhibitors / Q000008:administration & dosage*; D000328:Adult; D018687:Antidepressive Agents, Second-Generation / Q000008:administration & dosage*; D002908:Chronic Disease; D015283:Citalopram / Q000008:administration & dosage*; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D006801:Humans; D008297:Male; D009025:Morpholines / Q000008:administration & dosage*; D009771:Obsessive-Compulsive Disorder / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D000077593:Reboxetine; D055502:Secondary Prevention; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage*
D018759:Adrenergic Uptake Inhibitors; D018687:Antidepressive Agents, Second-Generation; D015283:Citalopram; D009025:Morpholines; D000077593:Reboxetine; D017367:Selective Serotonin Reuptake Inhibitors